News | August 30, 2021
Acute therapies drive overall pharma growth in July: Ind-Ra
The segment delivered strong sales growth of 20% YoY
The segment delivered strong sales growth of 20% YoY
This facility will integrate with existing Max hospitals and create a 2,300-bed contiguous medical hub spread over 23 acres. The first phase is to be ready by 2024
When used alongside rehabilitative exercise, this device may offer benefit to those who have lost function in their upper limbs due to ischemic stroke
The clinical research organisation located in Hyderabad is a USFDA inspected facility
The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually
First results demonstrate favourable tolerability of TQL-1055 at all dose levels
The company to receive upfront and milestone payments, in addition to royalties
Opaganib, a leading novel small molecule investigational oral pill in development for Covid-19, is a unique host targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of the disease
The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services
Trillium’s portfolio includes biologics that are designed to enhance the ability of patients’ innate immune system to detect and destroy cancer cells
Subscribe To Our Newsletter & Stay Updated
